Sanofi said today its earnings soared in the fourth quarter as lower restructuring costs offset...
Sanofi said Tuesday that its insulin U300 met its primary goals in a series of clinical trials,...
A government study offers a new theory on why the whooping cough vaccine doesn't seem to be...
Sanofi said its net profit slumped by over a fifth in the third quarter as it continued to suffer the effects of overpaying for acquisitions and a painful restructuring. Sanofi SA said its net profit fell 21 percent to 1.21 billion euros ($1.66 billion) in the July to September quarter, from 1.54 billion euros a year earlier.
A new high-dose flu vaccine for seniors works better than the standard shot in that age group, according to a long-awaited study by the vaccine's manufacturer. Experts say regular flu shots tend to be only about 30 to 40 percent effective in people 65 and older, who generally have weaker immune systems.
John Lazorchak, a former director of financial reporting at Summit-based Celgene Corp., and Mark Cupo, who held a similar position at Sanofi-Aventis, a France-based company with U.S. headquarters in Bridgewater, each pleaded guilty in federal court Monday to five counts of securities fraud.
Sanofi US and its consumer health business Chattem, Inc., have re-introduced Rolaids to stores across the United States. The iconic brand returns after a three-year hiatus in the marketplace and follows Chattem's acquisition of Rolaids earlier this year.
The comments by officials of the European Chamber of Commerce in China follow announcements about fines imposed on dairy suppliers over pricing issues and an investigation into possibly bribery by employees of drug manufacturers GlaxoSmithKline and Sanofi.
Pozen has announced that Sanofi will handle U.S. marketing of its experimental cardiovascular drugs PA8140 and PA32540. The French drugmaker will pay Pozen $15 million upfront, and Pozen could get another $20 million in payments based on milestones before approval of the products. The companies...
Four flu vaccine manufacturers have started or will soon start clinical trials on H7N9 vaccines, with four more expected to conduct trials in the late fall or early winter, says Dr. Robin Robinson. The work will cost the U.S. government about $100 million.
Chinese authorities have launched an investigation against French drugmaker Sanofi following a news report that accused the company of bribing hundreds of Chinese doctors in 2007. An unnamed whistleblower told the Guangzhou-based, state-owned 21st Century Business Herald that the French company had paid 503 doctors a total of $274,000 to prescribe Sanofi products, disguising the payments as grants for research programs.
Sanofi has announced that the Food and Drug Administration's Nonprescription Drugs Advisory Committee (NDAC) voted 10 to 6, with 2 abstentions, recommending approval of Nasacort ® AQ Nasal Spray (triamcinolone acetonide) for over-the-counter use in the U.S.
The Paris-based drugmaker reported Thursday that net profit shrank 62 percent to 444 million euros ($592 million) in the April to June quarter, as the loss of patent on once-popular blood-thinner Plavix compounded further massive financial charges related to the company's past mergers and acquisitions.
Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first lots of Fluzone@ (Influenza Virus Vaccine) for the 2013-2014 season have been released by the U.S. Food and Drug Administration (FDA) for U.S. distribution and were shipped July 24
Sanofi announced today that the first Phase 3 study results (EDITION I) for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus® (insulin glargine [rDNA origin] injection).
The National Institute for Health and Care Excellence issued draft guidance recommending against NHS reimbursement of Sanofi's Zaltrap (aflibercept) for treating patients with metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin containing regimen. The drug was approved for this use in Europe in February.
A group of Jefferies & Co. analysts said yesterday that drug companies are putting more emphasis on restructuring and spinning off parts of their business, and that those moves will be a critical factor in stock performance in 2013 and 2014.
A new asthma drug being developed by Sanofi and Regeneron Pharmaceuticals may help patients whose condition is not well controlled by existing medicines, according to the results of a small clinical trial released Tuesday. In the 12-week study, the number of asthma attacks or other outbreaks of symptoms decreased by 87 percent in those getting the drug, Dupilumab, compared with those getting a placebo.
France's antitrust authority on Tuesday fined Sanofi 40.6 million euros ($52.6 million) for a "smear campaign" designed to limit sales of generic versions of Plavix. The ruling on the drug, which last year generated global sales of nearly 2.1 billion euros ($2.7 billion), follows a complaint by Teva.
Berlin's renowned Charite hospital said Monday it plans to investigate allegations that patients in communist East Germany were used as unwitting guinea pigs in medical trials for Western drug companies. Claims that the dictatorship allowed tests that would have been considered unethical or even illegal in the West were first made shortly after German reunification in 1990, but no wrongdoing was found at the time.
French drug maker Sanofi said Thursday its net profit was slashed in the first quarter from a year earlier as falling sales and patent losses on key drugs combined to hammer earnings. Sanofi's net profit was €1 billion ($1.3 billion) in the January-March quarter, down 45 percent from €1.8 billion...
A government report reveals dangerous side effects of the popular sleeping pill Ambien, and its generic versions. Between 2005-2010 there was a 220% jump in visits to the emergency room. Ambien and its generic version have 44 million prescriptions were filled last year.
Shares of Amyris rose Thursday after Amyris' partner, Sanofi, started large-scale production of a malaria treatment using technology Amyris developed. Sanofi said it is beginning large-scale production of synthetic artemisinin, a key ingredient in malaria therapies. Artemisinin is derived from a wildflower called sweet wormwood, and it is the only effective medicine now widely used to cure malaria.
Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, announced today that it has submitted a decentralized marketing authorization application in Europe for a ' Q uadrivalent' influenza vaccine, a new advanced seasonal flu vaccine.
Genzyme, a Sanofi company, announced today Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) has approved once-daily, oral AUBAGIO® 14 mg as a new treatment indicated for patients with relapsing forms of multiple sclerosis (MS).
Sanofi SA said Friday that it's building a new medicine factory in Vietnam to supply drugs to that country and others in the region. The move is part of a fast-growing trend among major international pharmaceutical companies to put factories and research centers in emerging markets that the industry increasingly is targeting for growth.
The U.S. Justice Department is investigating drug maker Sanofi's disclosures to the Food and Drug Administration about different responses to its blockbuster blood thinner Plavix. The French company said in a filing with the Securities and Exchange Commission last week that it learned in June about the investigation.
DBV Technologies, creator of the Viaskin® allergy treatment, announced today that it entered into a strategic manufacturing agreement with Sanofi to produce Viaskin’s Active Pharmaceutical Ingredients (API), such as the peanut protein extract. Per the agreement, Sanofi will act as DBV’s Contract Manufacturing Organization (CMO).
- Page 1